The first Japanese biobank of patient‐derived pediatric acute lymphoblastic leukemia xenograft models

A lack of practical resources in Japan has limited preclinical discovery and testing of therapies for pediatric relapsed and refractory acute lymphoblastic leukemia (ALL), which has poor outcomes. Here, we established 57 patient‐derived xenografts (PDXs) in NOD.Cg‐Prkdc ( scid ) ll2rg ( tm1Sug )/Shi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Kuniaki, Kato, Itaru, Dobashi, Yuu, Imai, Jun‐ichi, Mikami, Takashi, Kubota, Hirohito, Ueno, Hiroo, Ito, Mamoru, Ogawa, Seishi, Nakahata, Tatsutoshi, Takita, Junko, Toyoda, Hidemi, Ogawa, Chitose, Adachi, Souichi, Watanabe, Shinya, Goto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633318/
https://www.ncbi.nlm.nih.gov/pubmed/35879192
http://dx.doi.org/10.1111/cas.15506
Descripción
Sumario:A lack of practical resources in Japan has limited preclinical discovery and testing of therapies for pediatric relapsed and refractory acute lymphoblastic leukemia (ALL), which has poor outcomes. Here, we established 57 patient‐derived xenografts (PDXs) in NOD.Cg‐Prkdc ( scid ) ll2rg ( tm1Sug )/ShiJic (NOG) mice and created a biobank by preserving PDX cells including three extramedullary relapsed ALL PDXs. We demonstrated that our PDX mice and PDX cells mimicked the biological features of relapsed ALL and that PDX models reproduced treatment‐mediated clonal selection. Our PDX biobank is a useful scientific resource for capturing drug sensitivity features of pediatric patients with ALL, providing an essential tool for the development of targeted therapies.

Ejemplares similares